0 avis
Terminal care in Parkinson’s disease : real-life use of continuous subcutaneous apomorphine infusion to improve patient comfort
Article
Background: There are currently no recommendations on the therapeutic management of Parkinson’s disease (PD) patients at the end of life.
Objective: To describe a cohort of patients with PD who benefited from continuous subcutaneous apomorphine infusion (CSAI) initiation at the end of their life as comfort care.
Methods: This real-life cohort includes 14 PD patients, who benefited from 24-h, low-dose CSAI (0.5–3 mg/h) in the context of terminal care. Patient’s comfort (pain, rigidity, and/or ability to communicate) and occurrence of CSAI-related side-effects (nausea/vomiting, cutaneous and behavioral manifestations) were evaluated based on medical records.
Results: All patients (age 62–94 years, disease duration 2–32 years) presented with late-stage PD and a compromised oral route. Treatment lasted from a few hours to 39 days. CSAI led to substantial functional improvement, with a good safety profile. Overall clinical comfort was deemed improved by the medical team, the patient, and/or caregivers.
Conclusions: CSAI might be a promising approach in PD terminal care, as it reduces motor symptoms and overall discomfort, with an apparent good safety profile. Use of the apomorphine pen, sublingual film or a classic syringe pump might be considered when apomorphine pumps are not available. Larger observational cohorts and randomized controlled trials are needed to establish the efficacy and tolerability of apomorphine in the context of terminal care and more broadly, in an advance care planning perspective.
https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd230201
Voir la revue «Journal of Parkinson's disease, 14»
Autres numéros de la revue «Journal of Parkinson's disease»
Consulter en ligne
Suggestions
Du même auteur
De la même série